Ninth consecutive year with solo booth; end-to-end CRO, CDO and CMO capabilities on display

CMC strategy cuts development timeline from 13 months to 9.5 months; cell culture productivity doubled

Next-generation organoid and AAV analytics technologies drive global push

Lee Tae-hee, senior vice president and head of Samsung Biologics' antibody cell purification process development team, delivers a presentation at an expert session Wednesday (local time). [Samsung Biologics]
Lee Tae-hee, senior vice president and head of Samsung Biologics' antibody cell purification process development team, delivers a presentation at an expert session Wednesday (local time). [Samsung Biologics]

Samsung Biologics has unveiled a sweeping set of next-generation manufacturing process innovations on the global stage, dramatically cutting drug development timelines and doubling production output.

The company announced Monday that it participated in BioProcess International 2026 (BPI), held in Boston from Tuesday to Friday (local time), showcasing its biopharmaceutical manufacturing process innovation strategies.

BPI brings together more than 250 companies and over 3,000 experts from around the world to discuss the latest technologies and partnerships across biopharmaceutical development, production and analytics.

Attending for the ninth consecutive year with a solo booth since 2018, Samsung Biologics highlighted its end-to-end capabilities spanning contract research (CRO), contract development (CDO) and CMO services.

Large-format graphics inside the booth spotlighted the company's proprietary organoid (miniature organ) technology, its differentiated CDO platform and its multi-modality treatment production capabilities.

A series of technical sessions further demonstrated the company's competitive edge. Lee Tae-hee, senior vice president and head of the antibody cell purification process development team, presented a molecule-specific process design approach built on an integrated chemistry, manufacturing and controls (CMC) framework. The strategy cut drug development time from 13 months to 9.5 months while maintaining high quality.

The poster session drew attention to S-Tensify, the company's cell culture intensification platform. Lee So-jung, head of the cell culture process development group, presented a strategy that raised final titer to twice the previous level by increasing cell culture density without compromising quality. Kim Young-hee, head of the cell line development group, shared a streamlined platform that controls quality and efficacy from the earliest stages of complex molecule development.

Samsung Biologics also showcased its capabilities in cell and gene therapy (CGT), a next-generation biopharmaceutical field. At the co-located Cell & Gene Therapy conference, Garcia Abigail, head of the AAV technology group, presented a full capsid analytical method for precisely evaluating the ratio of therapeutic genes inside adeno-associated virus (AAV) vectors, along with efficacy and stability guidelines.

Through its participation, Samsung Biologics aims to position itself as a comprehensive CDMO — one that goes beyond large-scale CMO capacity to encompass process efficiency from early development through next-generation biotech — and to maximize long-term lock-in partnerships with major pharmaceutical companies.

James Choi, executive vice president of sales support at Samsung Biologics, said it was meaningful to present the company's unrivaled end-to-end capabilities spanning CRO, CDO and CMO alongside its differentiated technologies. "We will continue to strengthen our position in the global biotech market through advanced technology and service," he added.


silverpaper@heraldcorp.com